Sera.Bo
SERA.BO operates in the investment banking and brokerage services sector, generating revenue primarily through financial advisory, asset management, and brokerage commissions.
Business. Sera Prognostics Inc (SERA.O) is a business support services company operating within the Industrial & Commercial Services sector. The firm generates service revenue through industrial services activities. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NASDAQ stock exchange.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sera Prognostics Inc (SERA.O) is a business support services company operating within the Industrial & Commercial Services sector. The firm generates service revenue through industrial services activities. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NASDAQ stock exchange.
SERA.BO maintains a strong liquidity position, with cash and equivalents amounting to INR 267.24 million, representing 7.0% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations without external financing. The debt-to-equity ratio of 0.07 suggests a conservative capital structure, with minimal reliance on debt financing.
Profitability metrics for SERA.BO show a return on equity (ROE) of 0.86% and a return on assets (ROA) of 0.66%. These figures are below the industry median for investment banking and brokerage services, indicating that the company is underperforming in terms of asset and equity utilization. The net income margin of 21.8% is relatively strong, but the operating margin of 22.4% suggests that operating expenses are consuming a significant portion of gross profit.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific data limits the ability to assess the performance of individual business lines.
SERA.BO's growth trajectory is modest, with revenue of INR 115.89 million in the latest reporting period. The outlook for the current fiscal year indicates a slight increase in revenue, but the magnitude of the growth is not specified. The company's capital expenditure of INR -11.84 million suggests a reduction in investment in physical assets, which may indicate a focus on cost optimization or a shift toward digital transformation.
Risk factors for SERA.BO include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's conservative debt structure and strong cash reserves mitigate liquidity concerns. However, the low ROE and ROA highlight the need for operational improvements to enhance profitability. The absence of dilution risk is a positive sign, but the company's reliance on a single revenue stream remains a concentration risk.
Recent events for SERA.BO include the latest financial filing, which provides updated financial metrics and confirms the company's current operational status. No significant regulatory or legal events were disclosed in the latest reports. The company's focus on maintaining a strong liquidity position and conservative capital structure is evident from the financial data.
- SERA.BO maintains a conservative capital structure with a low debt-to-equity ratio of 0.07.
- The company's ROE of 0.86% and ROA of 0.66% indicate underperformance relative to industry medians.
- Revenue is concentrated in a single business segment, increasing exposure to regional and regulatory risks.
- The company's liquidity position is strong, with cash and equivalents representing 7.0% of total assets.
- No immediate liquidity or dilution risks were detected, but operational improvements are needed to enhance profitability.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- General Counsel · Stock Option (right to buy) → Class A Common StockAcquired 68 550 @ $1,99grant · 2026-03-12
- Chief Financial Officer · Stock Option (right to buy) → Class A Common StockAcquired 68 550 @ $1,99grant · 2026-03-12
- Chief Commercial Officer · Stock Option (right to buy) → Class A Common StockAcquired 19 310 @ $1,99grant · 2026-03-12
- Chief Medical Officer · Stock Option (right to buy) → Class A Common StockAcquired 27 034 @ $1,99grant · 2026-03-12
- Director, Chief Executive Officer · Stock Option (right to buy) → Class A Common StockAcquired 239 442 @ $1,99grant · 2026-03-12
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SERA.BO Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$8M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- General Counsel · Class A Common StockSold 2 179 @ $2,01$4K · 2026-06-11
- Chief Commercial Officer · Class A Common StockSold 4 739 @ $2,01$10K · 2026-06-11
- Chief Financial Officer · Class A Common StockSold 2 037 @ $2,01$4K · 2026-06-11
- Director, Chief Executive Officer · Class A Common StockSold 6 990 @ $2,01$14K · 2026-06-11
- Chief Medical Officer · Class A Common StockSold 362 @ $2,01$728 · 2026-06-11
- Director, Chief Executive Officer · Class A Common StockSold 20 755 @ $2,08$43K · 2026-06-09
- Chief Financial Officer · Class A Common StockSold 5 440 @ $2,08$11K · 2026-06-09
- Director · Class A Common StockSold 1 560 @ $2,15$3K · 2026-06-08
- Chief Commercial Officer · Class A Common StockOther 3 168 @ $1,84$6K · 2026-05-29
- General Counsel · Class A Common StockOther 5 000 @ $1,84$9K · 2026-05-29
- Chief Commercial Officer · Class A Common StockOther 12 455 · 2026-03-12
- Director, Chief Executive Officer · Class A Common StockOther 154 440 · 2026-03-12
- General Counsel · Class A Common StockOther 44 215 · 2026-03-12
- Chief Medical Officer · Class A Common StockOther 17 437 · 2026-03-12
- Chief Financial Officer · Class A Common StockOther 44 215 · 2026-03-12
- Chief Financial Officer · Class A Common StockSold 1 019 @ $2,04$2K · 2026-03-11
- General Counsel · Class A Common StockSold 1 027 @ $2,04$2K · 2026-03-11
- Chief Information Officer · Class A Common StockSold 716 @ $2,04$1K · 2026-03-11
- Chief Scientific Officer · Class A Common StockSold 1 517 @ $2,04$3K · 2026-03-11
- Director, Chief Executive Officer · Class A Common StockSold 2 973 @ $2,04$6K · 2026-03-11
- Chief Data Officer · Class A Common StockSold 1 396 @ $2,04$3K · 2026-03-11
- Director, Chief Executive Officer · Class A Common StockSold 22 639 @ $1,90$43K · 2026-03-10
- Chief Financial Officer · Class A Common StockSold 6 069 @ $1,90$12K · 2026-03-10
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 32.3%Derived (calculated)
- Net margin (FY 2025-12-31): -39,417.3%Derived (calculated)
- Return on equity (FY 2025-12-31): -42.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -31.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.69xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.35xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 1,196.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -2.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 32.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 2.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -80.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 0.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -10.6%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 5.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 57.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 40.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 100.0%Derived (calculated)
- Total operating expenses (annual): USD 36.59MSEC XBRL filing
- Pre-tax income (annual): USD -31.93MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- Cost of revenue (annual): USD 164KSEC XBRL filing
- Total liabilities (annual): USD 26.52MSEC XBRL filing
- Cash & equivalents (annual): USD 3.94MSEC XBRL filing